Home4142 • TPE
add
Adimmune Corp
Previous close
$18.40
Day range
$18.30 - $18.55
Year range
$15.90 - $27.50
Market cap
7.90B TWD
Avg Volume
1.53M
P/E ratio
-
Dividend yield
-
Primary exchange
TPE
Market news
Financials
Income Statement
Revenue
Net income
(TWD) | Jun 2025info | Y/Y change |
---|---|---|
Revenue | 108.61M | 36.11% |
Operating expense | 162.65M | -36.71% |
Net income | -218.80M | 20.08% |
Net profit margin | -201.45 | 41.28% |
Earnings per share | — | — |
EBITDA | -149.51M | 40.99% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
(TWD) | Jun 2025info | Y/Y change |
---|---|---|
Cash and short-term investments | 1.93B | -14.23% |
Total assets | 8.27B | -5.09% |
Total liabilities | 3.37B | 1.24% |
Total equity | 4.90B | — |
Shares outstanding | 420.76M | — |
Price to book | 1.63 | — |
Return on assets | -6.23% | — |
Return on capital | -6.54% | — |
Cash Flow
Net change in cash
(TWD) | Jun 2025info | Y/Y change |
---|---|---|
Net income | -218.80M | 20.08% |
Cash from operations | -265.40M | 21.17% |
Cash from investing | 136.16M | 1,211.01% |
Cash from financing | -9.48M | 97.82% |
Net change in cash | -147.60M | 81.11% |
Free cash flow | -114.43M | 62.07% |
About
Adimmune Corporation is a Taiwanese biopharmaceutical company headquartered in Taichung. Originally founded in 1965 as Taiwan’s first vaccine laboratory, it later evolved into a modern vaccine manufacturer and contract development and manufacturing organization. The company is notable for being the only influenza vaccine manufacturer in Asia certified by both the European Union Good Manufacturing Practice and the U.S. Food and Drug Administration, and the*only human vaccine manufacturer in Taiwan operating under PIC/S GMP standards. Wikipedia
Founded
1965
Website
Employees
564